This content is current only at the time of printing. This document was printed on 4 December 2022. A current copy is located at https://apvma.gov.au/node/95731
You are here
Public Release Summary on florylpicoxamid in the product Telbek Adavelt active Fungicide
This consultation closed on 8 February 2022.
The APVMA is considering an application for registration of the product Telbek Adavelt active Fungicide containing 100 g/L of the approved active constituent florylpicoxamid, as an emulsifiable concentrate (EC) formulation. The product is intended for the control of Septoria tritici blotch (Zymoseptoria tritici) in wheat.
We invite comment from 11 January 2022 to 8 February 2022 on whether approval of the active constituent and registration of the product should be granted.
The APVMA is able to consider comments relating to the legislative grounds, including:
- occupational health and safety
- public health
- chemistry and manufacture
- residues in food
- environmental safety
- efficacy and target crop safety
Download the Public Release Summary on the evaluation of Telbek Adavelt active Fungicide.
For more information see page 40, APVMA Gazette No. 1, 11 January 2022.
Please note: Submissions will be published on the APVMA’s website, unless you have asked for the submission to remain confidential (see public submission coversheet).
Please lodge your submission with a public submission coversheet, which provides options for how your submission will be published.
Note that all APVMA documents are subject to the access provisions of the Freedom of Information Act 1982 and may be required to be released under that Act should a request for access be made.
Please send your written submission by email, post or fax to:
Case Management and Administration Unit
Australian Pesticides and Veterinary Medicines Authority
GPO Box 3262
Sydney NSW 2001
Phone: +61 2 6770 2300
The APVMA sought comments from interested stakeholders on whether registration of the product Telbek Adavelt active Fungicide containing 100 g/L of the approved active constituent florylpicoxamid should be granted, in a consultation that closed on 8 February 2022.
A total of one submission was received from an industry group.
A copy of the published submission is available on our website.
We have completed our review of the submission and finalised registration of the product.